Specialty Pharma Journal Specialty, Precision & Technology
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. Epizyme is now in the process of reopening enrollment …
Tag Archives: tazemetostat
September, 2018
December, 2015
-
30 December
First Patient Dosed in Epizyme’s Program for Genetically Defined Solid Tumors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that the first patient has been dosed in the phase 2 study of tazemetostat in adult patients with genetically defined tumors. The phase 1 dose escalation study in pediatric patients …